NLRP3 and Parkinson disease: A recent study has demonstrated that the NLRP3 inhibitor, MCC950, effectively suppressed microglial inflammasome activation, mitigating motor deficits, nigrostriatal dopaminergic degeneration and accumulation of α-Syn aggregates in multiple PD models [232].